Application of artemisinin to treatment of polycystic ovarian syndrome by regulating AMPK to promote white fat browning
The regulation of AMPK signaling pathway by artemisinin promotes browning of white fat, solves the shortcomings of existing PCOS treatment methods in regulating adipose tissue function and metabolic status, achieves a more comprehensive and safe treatment effect, and reduces metabolic disorders and obesity-related risk.
Patent Information
- Application Number
- CN202411181050.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-27
- Publication Date
- 2024-11-15
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing PCOS treatment methods are mostly symptomatic treatment, with single efficacy and many side effects, making it difficult to comprehensively improve the patient's metabolic status, especially in regulating adipose tissue function and white fat browning.
Through artemisinin, the AMPK signaling pathway is regulated, white adipocytes are activated to express the thermal-producing genes of brown adipocytes, promote the browning of white fat, reduce fat accumulation and insulin resistance, and improve metabolic disorders.
Effectively activate the AMPK signaling pathway, promote the conversion of white fat to brown fat, enhance energy consumption, improve insulin resistance and inflammation, and provide a safe and effective PCOS treatment method to reduce the risk of long-term complications.
Smart Images

Figure CN118948837A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to the application of artemisinin in regulating AMPK to promote the browning of white fat and then used in a drug for treating polycystic ovary syndrome. Background Art
[0002] Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder that affects approximately 6%-10% of women of childbearing age worldwide. The main characteristics of PCOS include irregular menstruation, ovulation disorders, elevated androgen levels, and polycystic ovaries. In addition, PCOS patients often have complications such as obesity, insulin resistance, and metabolic syndrome. The pathogenesis of PCOS is complex and has not yet been fully clarified, but metabolic disorders and abnormal adipose tissue function are considered to be one of its core pathological mechanisms.
[0003] Studies have shown that abnormally elevated androgen levels in PCOS patients interfere with normal lipid metabolism, leading to abnormal accumulation of adipose tissue, especially a significant increase in visceral fat. Human fat is mainly divided into white adipose tissue (WAT) and brown adipose tissue (BAT). WAT is mainly responsible for storing energy, while BAT promotes heat production and energy consumption through uncoupling protein 1 (UCP1) specifically expressed in mitochondria. Clinical studies have found that BAT levels in PCOS patients are significantly decreased. Therefore, activating BAT function may be a promising strategy for the treatment of PCOS. Current animal experiments have confirmed that exogenous transplantation of BAT can significantly improve serum hormone levels in PCOS rats, restore their normal estrous cycle, and improve insulin resistance.
[0004] AMPK (adenosine monophosphate-activated protein kinase) is an intracellular energy sensor that plays a key role in regulating energy metabolism, lipid metabolism, and glucose metabolism. Activating the AMPK signaling pathway can promote fatty acid oxidation, increase glucose uptake, and inhibit lipogenesis, so it is of great significance in improving insulin resistance and regulating adipose tissue function.
[0005] Currently, the treatment of PCOS mainly focuses on relieving symptoms and preventing complications, including the use of oral contraceptives to regulate the menstrual cycle, anti-androgen drugs to improve hirsutism and acne symptoms, ovulation-inducing drugs (such as clomiphene and letrozole) to help women conceive, and insulin sensitizers (such as metformin) to improve insulin resistance. However, existing therapies are mostly symptomatic, and long-term use may bring a series of side effects, such as drug dependence, metabolic abnormalities, and adverse effects on the cardiovascular system. Therefore, finding new therapeutic drugs with good efficacy and fewer side effects has become an urgent problem to be solved.
[0006] The treatment methods for PCOS mainly include drug therapy, lifestyle intervention and surgical treatment. Among them, drug therapy mainly relies on hormone regulation, insulin sensitizers and anti-androgen drugs, but these methods usually target a single symptom or pathological process and are difficult to comprehensively improve the patient's metabolic state. In the existing technical solutions, metformin is a commonly used insulin sensitizer and is widely used in the treatment of PCOS. Metformin regulates glucose and lipid metabolism by activating the AMPK signaling pathway, thereby improving insulin sensitivity. However, the main effects of metformin are concentrated in the liver and muscle tissue, and the effect on adipose tissue, especially the browning of white fat, is relatively limited. Another existing technology is to use β-adrenergic receptor agonists (such as mirabegron) to promote the thermogenic function of brown fat cells to increase energy consumption. This type of drug promotes fat metabolism through a mechanism different from AMPK, but its application in the treatment of PCOS has not been widely verified and may be accompanied by certain cardiovascular risks. In addition, there are studies trying to use PPARγ agonists (such as rosiglitazone) to regulate the differentiation and function of adipocytes. However, long-term use of such drugs may lead to weight gain and an increased risk of heart disease.
[0007] As a drug derived from nature, artemisinin is widely used due to its excellent antimalarial effect, but its application in the treatment of PCOS has not been reported. Recent studies have shown that artemisinin also has multiple biological activities and can affect metabolic processes by regulating the AMPK signaling pathway. It is also expected to become a safe and effective new PCOS treatment drug due to its low toxicity and significant effect in regulating energy metabolism. At the same time, although the existing technology has made certain progress in regulating adipose tissue function and improving metabolic status, it generally has the problems of single efficacy and more side effects. Exploring new applications of artemisinin in the treatment of PCOS, especially the mechanism of promoting the browning of white fat by regulating the AMPK signaling pathway, has important clinical significance and broad application prospects. Therefore, the present invention proposes a new scheme to promote the browning of white fat by regulating the AMPK signaling pathway through artemisinin, which is expected to overcome the shortcomings of the existing technical schemes, provide a more comprehensive and safer PCOS treatment method, provide a new idea and method for the treatment of PCOS, and open up a new direction in this field. Summary of the invention
[0008] The technical problem to be solved by the present invention is to provide an application of artemisinin in regulating AMPK to promote the browning of white fat for the treatment of polycystic ovary syndrome. By applying artemisinin as a single ingredient to treat PCOS, based on its unique pharmacological effects and potential multi-target mechanisms, the estrous cycle, serum hormone levels and ovarian function of PCOS patients are regulated, thereby effectively improving the symptoms of PCOS and reducing the risk of long-term complications.
[0009] In order to solve the above technical problems, an embodiment of the present invention provides the use of artemisinin to regulate AMPK and promote the browning of white fat in the treatment of polycystic ovary syndrome.
[0010] The embodiments of the present invention also provide the use of artemisinin in the preparation of a drug for regulating AMPK to promote the browning of white fat for the treatment of polycystic ovary syndrome.
[0011] Furthermore, the main ingredients are artemisinin and its derivatives.
[0012] Furthermore, the artemisinin activates the AMPK signaling pathway, induces white fat cells to express thermogenic genes similar to those of brown fat cells, promotes the browning of white fat, and treats polycystic ovary syndrome by reducing fat accumulation, improving insulin resistance, and reducing inflammation levels in the body.
[0013] Furthermore, the effective dosage of artemisinin and its derivatives in the drug for treating polycystic ovary syndrome is 40 to 160 mg / kg.
[0014] Furthermore, the administration form includes oral administration or injection administration.
[0015] The beneficial effects of the above technical solution of the present invention are as follows:
[0016] The present invention can effectively activate the AMPK signaling pathway in PCOS patients, promote the conversion of white fat to brown fat, thereby enhancing energy consumption, reducing fat accumulation, and improving insulin resistance and chronic inflammation. This technology can not only alleviate the metabolic symptoms of PCOS, but also improve the overall health of patients, providing a safe, effective and innovative method for treating polycystic ovary syndrome. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 This is a graph showing the effect of artemisinin (ART) on the estrous cycle of PCOS rats;
[0018] Figure 2 This is a graph showing the changes in the effects of ART on ovarian tissue lesions in PCOS rats;
[0019] Figure 3 This is a comparison chart of the effects of ART on hormone levels in PCOS rats;
[0020] Figure 4 This is a comparison chart of the effect of ART on litter size in PCOS rats;
[0021] Figure 5 This is a graph showing the effect of ART on the body weight of PCOS rats;
[0022] Figure 6 This is a comparison chart of the effects of ART on blood lipid levels in PCOS rats;
[0023] Figure 7 This is a comparison chart of the effects of ART on fat weight in PCOS rats;
[0024] Figure 8 This is the effect of ART on WAT tissue morphology in PCOS rats;
[0025] Fig. 9 This is the effect of ART on BAT tissue morphology in PCOS rats;
[0026] Fig.10 This is a diagram showing the effect of ART on WB detection of AMPK and UCP1 protein expression in adipose tissue;
[0027] Fig.11 This figure shows the effect of ART on the number of UCP1-positive cells in adipose tissue using immunohistochemistry. DETAILED DESCRIPTION
[0028] In order to make the technical problems, technical solutions and advantages to be solved by the present invention more clear, a detailed description will be given below with reference to the accompanying drawings and specific embodiments.
[0029] The technical problem to be solved by the present invention is to provide a method for treating polycystic ovary syndrome (PCOS) by promoting the browning of white fat by regulating the AMPK (adenylate-activated protein kinase) pathway using artemisinin (ART), aiming to solve the deficiencies of existing treatment methods in regulating adipose tissue metabolism and improving abnormal energy metabolism.
[0030] Specifically, the present invention activates the AMPK signaling pathway through the application of artemisinin and its derivatives, thereby promoting the transformation of white fat cells into brown fat cells (i.e., browning of white fat), increasing energy consumption, reducing fat accumulation, improving insulin resistance, and alleviating PCOS-related metabolic disorders.
[0031] Furthermore, the present invention uses artemisinin and its derivatives as the main active ingredients, which can be obtained by chemical synthesis or extraction from natural Artemisia annua plants. The purity of artemisinin should reach pharmaceutical grade to ensure its safety and effectiveness in treatment.
[0032] Activate the AMPK signaling pathway through artemisinin and its derivatives. Artemisinin can directly or indirectly activate AMPK, phosphorylate it, and then start the downstream metabolic regulation mechanism. Through the activation of AMPK, fatty acid oxidation and glucose uptake are enhanced, and fat synthesis is inhibited, thereby improving energy metabolism overall.
[0033] Activating the AMPK signaling pathway can induce white fat cells to express thermogenic genes similar to brown fat cells (such as UCP1), causing white fat cells to gradually transform into cells with brown fat functions (i.e., white fat browning). The process of white fat browning can increase the body's basal metabolic rate and increase energy consumption, thereby effectively reducing fat accumulation and improving obesity.
[0034] By promoting the browning of white fat, artemisinin can reduce fat accumulation in PCOS patients, improve insulin resistance, reduce inflammation levels in the body, relieve metabolic symptoms of PCOS, and also improve patients' hormone levels and regulate ovarian function, thereby providing comprehensive treatment for PCOS patients in many aspects.
[0035] Through this mechanism, the present invention not only helps to reduce the weight and fat distribution abnormalities of PCOS patients, but also reduces the risk of metabolic complications associated with PCOS. This technology provides an innovative and effective metabolic intervention strategy for the treatment of PCOS, especially by regulating the cell energy sensor AMPK to accurately improve the metabolic state of patients.
[0036] In terms of drug formulation and administration, artemisinin and its derivatives can be prepared into oral tablets, capsules or injections. The specific preparation form can be selected according to the patient's needs. The dosage and frequency of administration of the drug should be adjusted according to the patient's specific condition, weight and metabolic state to achieve the best therapeutic effect.
[0037] In clinical applications, the therapeutic effect of artemisinin can be evaluated by regularly monitoring the patient's metabolic indicators (such as blood sugar, insulin, lipid levels) and weight changes. At the same time, the degree of browning of white fat can be observed through imaging and histological tests to further verify its therapeutic effect on PCOS.
[0038] The present invention is further described below in conjunction with specific embodiments.
[0039] Model building and grouping
[0040] 48 4-week-old female SD rats were randomly divided into 6 groups (n=6) after one week of adaptive feeding, including normal control group, PCOS group, PCOS+metformin (metformin, 270 mg / kg) group, PCOS+ARTL (40 mg / kg) group, PCOS+ARTM (80 mg / kg) group and PCOS+ARTH (160 mg / kg) group. When constructing the PCOS model, rats were subcutaneously injected with DHEA 0.6 mg / kg + 0.2 mL soybean oil in the back of the neck every day for 21 consecutive days. Then different doses of ART or metformin were administered for 21 days, and the control group and PCOS group were gavaged with the same volume of sodium carboxymethylcellulose.
[0041] Example 1: Effect of ART on the estrous cycle of PCOS rats
[0042] Each group was fed continuously and given DHEA or drug intervention. Gram staining of vaginal smears was performed for about 2 consecutive weeks starting from the 28th day of feeding to observe the changes in the estrous cycle of each group of rats.
[0043] The results are as follows Figure 1 As shown, Figure 1 A shows the estrous cycle changes of rats in each group; Figure 1 B is the statistics of estrous cycle changes in rats in each group, * represents the comparison between the Control group and the PCOS group, # represents the comparison between the PCOS group and the drug-treated group; ****P<0.001, #P<0.05, ##P<0.01; Figure 1 C is a diagram showing the effects of ART on PCOS rats under Gram staining, Proestrous (P): proestrous; Eatrous (E): estrous; Metestrous (M): metestrous; Diestrous (D): diestrus.
[0044] Figure 1 AB showed that the estrous cycle of rats in the Control group was regular, with a cycle of 4-5 days, while the estrous cycle of the PCOS group was significantly disordered and irregular. The estrous cycle of the PCOS+metformin group improved after 1 day and one week after the influence of metformin, and the regularity of the estrous cycle was restored; the regularity of the estrous cycle of the PCOS+ARTL group and the PCOS+ARTM group was also improved after 9 days and 5 days respectively. Figure 1 C shows a reference vaginal smear showing cell changes at various stages of the rat estrous cycle.
[0045] The above comparison shows that the estrous cycle of the normal control group rats in the four stages of proestrus, estrus, metestrus and estrus is regular. Compared with the normal control group, the estrous cycle of the PCOS group rats is continuously in estrus or estrus, and the regularity of the estrous cycle is lost. Compared with the PCOS group, the estrous cycle of the metformin group has recovered regularity. After ART intervention, the PCOS rats in the ART-M and ART-H groups have recovered regular estrous cycles, indicating that the metabolic state of PCOS patients can be improved by activating the AMPK signaling pathway to promote the browning of white fat.
[0046] Example 2: Effect of ART on the restoration of ovarian tissue damage in PCOS rats
[0047] After the 21-day administration cycle, the ovarian tissues were collected, fixed with 4% paraformaldehyde, dehydrated with gradient alcohol, embedded in paraffin and sliced, and then stained with hematoxylin-eosin (HE) to observe the morphological changes of the ovarian tissues of the rats in each group. Figure 2 This is a diagram showing the effect of ART on ovarian tissue lesions in PCOS rats. In the figure, CL: Corpus luteum; F: follicle; CF: Cystic follicle; AF: Atretic follicle; the arrow points to the granulosa cell layer.
[0048] Ovarian morphology showed that the number of follicles and corpora lutea at all stages of development in the ovaries of rats in the normal control group was large, atretic follicles were rare, and the ovarian granulosa cell layer was distributed in multiple layers. The number of corpora lutea in the ovaries of the PCOS group was small, the number of cystic follicles and atretic follicles increased, and the number of granulosa cell layers decreased. Compared with the PCOS group, the number of corpora lutea in the ovaries of rats in the positive control metformin group increased significantly, and the number of cystic ovaries decreased. The number of cystic follicles and atretic follicles in rats in each dose group of ART decreased, the number of corpora lutea increased, and the number of granulosa cell layers also increased, especially in the medium and high dose groups. This shows that ART can improve the development of ovarian follicles in PCOS rats and restore ovarian tissue damage in PCOS rats.
[0049] Example 3: Effects of ART on hormone levels in PCOS rats
[0050] After 21 days of administration, the blood of rats in each group was collected through the abdominal aorta, left to stand at room temperature for 1 hour, centrifuged at 4°C, 3000rpm for 20 minutes, the upper serum was aspirated, and stored in a -80°C refrigerator; according to the instructions of the ELISA kit, the serum T, E2, P, LH, and FSH levels were measured, and the LH / FSH value was calculated to detect the endocrine changes of rats in each group. Figure 3 A is the serum estrogen E2 level of rats in each group; Figure 3 B is the serum progesterone P level in each group; Figure 3 C is the serum testosterone T level of each group; Figure 3 D is the serum luteinizing hormone LH level in each group; Figure 3 E is the serum follicle stimulating hormone (FSH) level in each group; Figure 3 F is the LH / FSH ratio of each group. In the figure, * represents the comparison between the Control group and the PCOS group, # represents the comparison between the PCOS group and the drug-treated group; **P<0.01, ****P<0.001, #P<0.05, ##P<0.01.
[0051] The above comparisons show that compared with the Control group, the P and FSH contents decreased, and the T, LH and LH / FSH contents increased significantly; compared with the PCOS group, the P level in the positive control metformin group increased significantly, and the T and LH levels decreased significantly; after ART intervention, the E2 content in the serum of rats in each dose group increased, and the ARTH group increased most significantly, and the P level increased significantly. This shows that ART treatment can reverse the reproductive hormone levels of PCOS rats.
[0052] Example 4: Effect of ART on the Fertility of PCOS Rats
[0053] After 21 days of drug administration, the fertility of the grouped rats was tested. The specific operation method was as follows: at 5 pm, a 3-month-old SD male rat was caged with two female rats. After 7 days, the male and female rats were separated. The fertility of each group of rats was observed within 30 days, and the number of offspring was recorded and statistically analyzed. Figure 4 This is a comparative diagram of the effect of ART on the litter size of PCOS rats. In the figure, * is compared with the Control group, # is compared with the PCOS group. N=8; ***P<0.001, #P<0.05.
[0054] The above comparison results show that compared with the control group, the litter size of rats in the PCOS model group was significantly reduced, while the litter size increased after ART intervention, which indicates that ART treatment can improve the fertility of PCOS rats.
[0055] Example 5: Effect of ART on the Body Weight of PCOS Rats
[0056] Each group was fed and intervened for 30 days, and the daily body weight of rats in each group was recorded. Figure 5 As shown, Figure 5 A is the weight change of rats in each group during the drug administration period. Figure 5 B is the comparison of body weight of rats in each group after drug administration, # compared with PCOS group, ## P < 0.01, n = 8. This result shows that compared with PCOS group, body weight of PCOS + ARTM and PCOS + ARTH groups decreased significantly, indicating that ART treatment can reduce the body weight of PCOS rats.
[0057] Example 6: Effect of ART on blood lipid levels in PCOS rats
[0058] Similar to the operation in Example 3, serum was collected from rats in each group, and blood lipid content and insulin level were detected by biochemical method or ELISA method. Figure 6 This is a comparison chart of ART on blood lipid levels in PCOS rats, among which, Figure 6 A is the serum triglyceride TG content of each group; Figure 6 B is the comparison of serum insulin FINS levels among the groups; Figure 6 C is the serum total cholesterol TC content of each group; Figure 6 D is the comparison of serum high-density lipoprotein HDL-C content among the groups; Figure 6 E is the comparison of serum low-density lipoprotein LDL-C content in each group. In the figure, N = 8; * represents the comparison between the Control group and the PCOS group, # represents the comparison between the PCOS group and the drug-treated group; **P < 0.01, ***P < 0.001, #P < 0.05, ##P < 0.01, ###P < 0.001.
[0059] The above comparisons show that compared with the control group, the serum TG, FINS and LDL-C levels of PCOS rats increased significantly, and the HDL-C level decreased significantly; compared with the PCOS group, the TG and FINS levels of the positive control metformin group decreased significantly; compared with the PCOS group, the serum TG and FINS levels of rats in each dose group decreased significantly after ART intervention, and the HDL-C level in the high dose group increased significantly. This indicates that ART treatment can reverse the blood lipid level of PCOS rats.
[0060] Example 7: Effect of ART on fat weight in PCOS rats
[0061] After the administration, inguinal fat and BAT were collected and weighed. Figure 7 This is a comparison chart of the effects of ART on fat weight in PCOS rats, Figure 7 A is the comparison of SAT tissue weights in each group; Figure 7B is the comparison of BAT tissue weight, where * is compared with the normal control group, # is compared with the PCOS group; *P<0.05, ##P<0.01, ####P<0.001. SAT: subcutaneous adipose tissue (inguinal fat); BAT: brown adipose tissue.
[0062] The above comparison shows that compared with the control group, the BAT weight of the PCOS group was significantly reduced. After ART intervention, the SAT weight of the ARTM and ARTH groups decreased significantly, and the BAT weight of the ARTH group increased. This shows that ART treatment can increase the BAT weight of PCOS rats and reduce the weight of white fat such as SAT and VAT.
[0063] Example 8: Effect of ART on fat morphology in PCOS rats
[0064] After the administration cycle, the visceral fat tissue specimens of rats in each group were fixed with 4% paraformaldehyde, dehydrated, embedded and sliced, and then HE staining was performed to observe the effect of ART on visceral fat in PCOS rats.
[0065] The results are as follows Figure 8 Compared with the control group, the WAT cells in the PCOS group were more hypertrophic; compared with the PCOS group, after metformin and ART intervention, the WAT volume in the metformin group became smaller and the number increased. In the ART intervention group, the fat cell volume in each group gradually decreased and the cell number increased with the increase of the dose. Fig. 9 As shown in the figure, compared with the control group, the whitening of BAT cells in the PCOS group increased; compared with the PCOS group, after metformin and ART intervention, the number of typical multi-chamber-like cells in the metformin group increased, and the volume of fat cells in each group gradually decreased with the increase of dose in the ART intervention group, while the number of cells increased. These pathological results further indicate that ART treatment can affect the morphology of fat cells in PCOS rats, thereby having the effect of anti-obesity and regulating energy metabolism.
[0066] Example 9: Effect of ART on the expression of specific thermogenic protein UCP1 in adipose tissue mitochondria
[0067] Since the AMPK signaling pathway has been shown to play an important role in regulating lipid metabolism, this study further explored whether artemisinin could regulate the expression of the specific thermogenic protein UCP1 in mitochondria by activating the AMPK pathway and whether it was involved in improving the symptoms of PCOS rats. By using WT, qPCR and immunohistochemistry experimental techniques, the effects of artemisinin on the expression of AMPK and UCP1 in brown adipose tissue BAT were observed. Fig.10 and 11 shown.
[0068] Fig.10A is Western blot detection of UCP1 and AMPK protein expression, Fig.10 B and Fig.10 C is the statistical result of UCP1 and AMPK protein expression. Among them, * compared with the normal control group, # compared with the PCOS group; **P<0.01, ***P<0.001; #P<0.05, ###P<0.01. Fig.11 Immunohistochemistry was used to detect the effect of ART on UCP1 protein in adipose tissue. *Compared with the Control group, #Compared with the PCOS group; **P<0.01, ****P<0.001, #P<0.05, ##P<0.01.
[0069] The above comparison results show that compared with the control group, the protein expression levels of AMPK and UCP1 in the PCOS group were significantly decreased; compared with the PCOS group, the protein expression levels of AMPK and UCP1 increased with the increase of dose after ART intervention, and the protein expression levels of AMPK and UCP1 in the ARTH group were significantly increased ( Fig.10 ). This suggests that AMPK can promote thermogenesis and reduce lipid accumulation in the body by regulating the expression of UCP1 in BAT, which is involved in metabolic disorders in rats with PCOS. Furthermore, immunohistochemistry showed that the number of UCP1-positive cells in the fat of rats in the PCOS group was significantly less than that in the normal control group. After ART intervention, the number of UCP1-positive cells in adipose tissue increased significantly compared with the PCOS group, suggesting that it can increase the browning degree of subcutaneous adipose tissue in the inguinal region of PCOS rats ( Fig.11 ). As reviewed, the therapeutic effect of ART on PCOS rats may be partly attributed to the increase in endogenous BAT activity and the increase in the browning degree of WAT.
[0070] The beneficial effects brought by the technical solution of the present invention mainly include the following aspects:
[0071] 1. Enhance energy metabolism and reduce obesity: The present invention regulates the AMPK signaling pathway through artemisinin, promotes the browning of white fat, and significantly improves the body's basal metabolic rate. By increasing fatty acid oxidation and calorie consumption, it effectively reduces fat accumulation, helps PCOS patients lose weight, especially reduces visceral fat, thereby alleviating metabolic problems related to obesity.
[0072] 2. Improve insulin sensitivity and relieve metabolic disorders: Artemisinin activates AMPK to improve insulin sensitivity, lower blood sugar levels, and reduce insulin resistance. For PCOS patients, this can significantly improve sugar metabolism disorders, reduce the risk of type 2 diabetes, and help balance hormone levels in the body, further improving PCOS symptoms.
[0073] 3. Reduce chronic inflammation and improve overall health: By promoting the browning of white fat, artemisinin can reduce the level of inflammatory factors in PCOS patients and alleviate the chronic inflammatory state. Chronic inflammation is an important factor in PCOS and its complications. By reducing inflammation, the present invention helps to improve the overall health of patients and reduce the incidence of complications such as cardiovascular diseases.
[0074] 4. Multi-target comprehensive treatment to improve treatment effect: The present invention not only improves PCOS symptoms by regulating energy metabolism and lipid metabolism, but also achieves comprehensive treatment of PCOS through multi-target regulation of the AMPK signaling pathway, involving fatty acid oxidation, sugar metabolism, adipose tissue function and other aspects. Compared with a single treatment method, the present invention provides a more comprehensive and more effective treatment strategy that can significantly improve the treatment effect.
[0075] 5. High safety and few side effects: Artemisinin, as a natural compound, has high safety and few side effects. The present invention uses these advantages of artemisinin to provide a low-risk treatment option for PCOS patients, which is particularly suitable for long-term use and can avoid common side effects in traditional treatments, such as weight gain, hormone disorders, etc.
[0076] 6. Wide applicability: The present invention is not only suitable for PCOS patients, but also can be used to treat other diseases related to metabolic disorders and obesity, such as type 2 diabetes, metabolic syndrome, etc. Therefore, the present invention has a wide range of application prospects and can bring benefits to more patient groups.
[0077] In summary, the present invention provides a novel treatment method for promoting the browning of white fat by regulating AMPK through artemisinin, which can effectively alleviate the symptoms of polycystic ovary syndrome, improve the metabolic state and overall health of patients, and has significant clinical application value and broad application prospects.
[0078] The above is a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. Application of artemisinin in regulating AMPK to promote browning of white fat in the treatment of polycystic ovary syndrome.
2. The application of artemisinin in the preparation of drugs for regulating AMPK to promote the browning of white fat for the treatment of polycystic ovary syndrome.
3. The use of artemisinin according to claim 2 in the preparation of a drug for regulating AMPK to promote browning of white fat for the treatment of polycystic ovary syndrome, characterized in that: The main ingredients are artemisinin and its derivatives.
4. The use of artemisinin according to claim 2 in the preparation of a drug for regulating AMPK to promote browning of white fat for the treatment of polycystic ovary syndrome, characterized in that: The artemisinin activates the AMPK signaling pathway, induces white fat cells to express the thermogenic genes of brown fat cells, promotes the browning of white fat, and treats polycystic ovary syndrome by reducing fat accumulation, improving insulin resistance, and reducing inflammation levels in the body.
5. The use of artemisinin according to claim 2 in the preparation of a drug for regulating AMPK to promote browning of white fat for the treatment of polycystic ovary syndrome, characterized in that: The effective dosage of artemisinin and its derivatives in the drug for treating polycystic ovary syndrome is 40-160 mg / kg.
6. The use of artemisinin according to claim 2 in the preparation of a drug for regulating AMPK to promote browning of white fat for the treatment of polycystic ovary syndrome, characterized in that: The administration forms include oral administration or injection administration.
